Reducing Cis-Element Plasmid Input for rAAV Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated virus (rAAV) vectors are costly and inefficient, particularly when packaging cytotoxic transgenes, as they require high amounts of cis-element plasmids, which can be detrimental to host cell fitness.
Innovation Solution
The method involves significantly reducing the cis-element plasmid input by 10-fold to 100-fold relative to other input plasmids in a triple transfection protocol, maintaining high rAAV production yields and enabling efficient packaging of cytotoxic transgenes while reducing costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high amounts of cis-element plasmid are used in triple transfection protocol, then rAAV production yield is maintained, but production cost increases and host cell fitness is compromised
Solution Approach 1:
The patent changes the concentration parameter of cis-element plasmid from traditional high amounts to substantially reduced amounts (10-fold to 100-fold reduction). This parameter change resolves the contradiction by demonstrating that low cis-element plasmid concentrations can maintain rAAV production yield while reducing production costs and improving host cell fitness, contrary to conventional wisdom that required high plasmid amounts for adequate production
Solution Approach 2:
The patent applies partial action by using only the minimum necessary amount of cis-element plasmid (10-100 times less than traditional protocols) to achieve adequate rAAV production. This resolves the contradiction by showing that excessive plasmid amounts are not needed, and partial amounts suffice to maintain productivity while reducing harmful effects and costs
2Productivity
If high amounts of cis-element plasmid are used to ensure adequate rAAV genome availability, then production yield is maintained, but monetary costs increase significantly
Solution Approach 1:
The patent changes the concentration parameter of cis-element plasmid from traditional high amounts to substantially reduced amounts (10-fold to 100-fold reduction). This parameter change resolves the contradiction by demonstrating that low cis-element plasmid concentrations can maintain rAAV production yield while reducing production costs, directly addressing the cost-effectiveness issue
3Reliability
If high amounts of cis-element plasmid are used in transfection, then rAAV genome availability is sufficient, but host cell fitness is compromised
Solution Approach 1:
The patent changes the concentration parameter of cis-element plasmid to substantially reduced amounts. This resolves the contradiction by showing that sufficient rAAV genome availability can be achieved with low plasmid concentrations, thereby eliminating the harmful effect of compromised host cell fitness while maintaining reliable genome availability for packaging
Solution Approach 2:
The patent converts the potential harm of cis-element plasmid overuse into benefit by deliberately using reduced amounts. This resolves the contradiction by transforming the situation where low plasmid amounts might seem to cause insufficient genome availability into a beneficial outcome where adequate genome availability is achieved with minimal plasmid, thereby protecting host cell fitness
Data Source
AI summary
In some aspects, the disclosure relates to methods for improving titer and yield of viral vector production. In some embodiments, the disclosure relates to compositions and methods of using same, wherein the compositions comprise (i) a cis-element nucleic acid comprising a transgene: (ii) a helper nucleic acid encoding adenoviral helper genes; and (iii) a packaging nucleic acid encoding Rep and/or Cap genes: wherein the ratio of (i): (ii) and/or the ratio of (i): (iii) is between 0.01:1 and 0.1:1.